Eris Lifesciences (NSE:ERIS) Margin of Safety % (DCF FCF Based): -791.92% (As of Jun. 28, 2026)


NSE:ERIS Eris Lifesciences Ltd NSE:ERIS
91 GF Score
Price ₹1,459.00
GF Value ₹1,642.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences Margin of Safety % (DCF FCF Based)?

Eris Lifesciences NSE:ERIS -0.50% 91 Margin of Safety % (DCF FCF Based) is -791.92% as of Jun. 28, 2026. GuruFocus rates NSE:ERIS with a GF Score™ of 91/100 and a GF Value™ of ₹1,642.12 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-28), Eris Lifesciences's Predictability Rank is 4.5-Stars. Eris Lifesciences's intrinsic value calculated from the Discounted FCF model is ₹634.22 and current share price is ₹1459.00. Consequently,

Eris Lifesciences's Margin of Safety % (DCF FCF Based) using Discounted FCF model is -791.92%.

NSE:ERIS vs ZTS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eris Lifesciences Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Margin of Safety % (DCF FCF Based) falls into.


NSE:ERIS
91GF Score
Eris Lifesciences Ltd NSE:ERIS
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences Margin of Safety % (DCF FCF Based) Calculation

Eris Lifesciences's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(163.58-1459.00)/163.58
=-791.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

What does a Margin of Safety % (DCF FCF Based) of -791.92% mean?
Eris Lifesciences (NSE:ERIS) has a Margin of Safety % (DCF FCF Based) of -791.92% as of Jun. 28, 2026. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Eris Lifesciences.
Is Eris Lifesciences' Margin of Safety % (DCF FCF Based) too high?
Eris Lifesciences' current Margin of Safety % (DCF FCF Based) is -791.92%. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Margin of Safety % (DCF FCF Based) compare to ZTS?
Eris Lifesciences' Margin of Safety % (DCF FCF Based) of -791.92% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF FCF Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF FCF Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF FCF Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF FCF Based) mean?
A high Margin of Safety % (DCF FCF Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Eris Lifesciences. Eris Lifesciences's current Margin of Safety % (DCF FCF Based) is -791.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.12, compared to a current price of ₹1,459.00 — trading 11.2% below its estimated fair value. The current Margin of Safety % (DCF FCF Based) is -791.92%. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF FCF Based) calculated?
Margin of Safety % (DCF FCF Based) is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current Margin of Safety % (DCF FCF Based) is -791.92% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,459.00 is trading 11.2% below its estimated GF Value™ of ₹1,642.12. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for NSE:ERIS:

  • Margin of Safety % (DCF FCF Based): -791.92%
  • GF Value™: ₹1,642.12 vs. price of ₹1,459.00 (11.2% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eris Lifesciences Business Description

Other Exchanges 540596:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score

Get the complete analysis for NSE:ERIS

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,459.00
Price
₹1,642.12
GF Value